Vincerx Pharma (VINC) SEC Filings & 10K Form $0.04 0.00 (-1.28%) As of 08/15/2025 12:19 PM Eastern Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Vincerx Pharma SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel DateFilerForm TypeView07/29/20254:55 PMSAGE RHINO CAPITAL LLC (Filed by)Vincerx Pharma (Subject)Form SCHEDULE 13G/A07/16/20253:14 PMVincerx Pharma (Filer)Form DEFA14A07/07/20253:23 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 07/07/20253:27 PMVincerx Pharma (Filer)Form DEFA14A06/18/20253:18 PMVincerx Pharma (Filer)Form DEFA14A05/15/20252:13 PMARMISTICE CAPITAL, LLC (Filed by)Vincerx Pharma (Subject)Form SCHEDULE 13G/A05/12/20253:49 PMVincerx Pharma (Filer)Form DEF 14A05/04/202511:15 PMVincerx Pharma (Filer)Form EFFECT05/04/202511:15 PMVincerx Pharma (Filer)Form EFFECT05/04/202511:15 PMVincerx Pharma (Filer)Form EFFECT05/01/20254:06 PMVincerx Pharma (Filer)Form POS AM Get the Latest News and Ratings for VINC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. 05/01/20254:07 PMVincerx Pharma (Filer)Form POS AM05/01/20254:08 PMVincerx Pharma (Filer)Form POS AM05/01/20254:10 PMVincerx Pharma (Filer)Form S-8 POS05/01/20254:11 PMVincerx Pharma (Filer)Form S-8 POS05/01/20254:11 PMVincerx Pharma (Filer)Form S-8 POS05/01/20254:12 PMVincerx Pharma (Filer)Form S-8 POS05/01/20254:13 PMVincerx Pharma (Filer)Form S-8 POS04/30/20253:41 PMVincerx Pharma (Filer)Form PRE 14A04/17/20253:52 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 04/11/20253:03 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 04/02/202511:15 PMVincerx Pharma (Filer)Form EFFECT03/31/20253:02 PMVincerx Pharma (Filer)Form S-3/A03/18/20258:02 AMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 03/18/20258:05 AMVincerx Pharma (Subject)Form 42502/12/20257:30 AMProsight Management, LP (Filed by)Vincerx Pharma (Subject)Form SCHEDULE 13G/A02/11/20256:09 PMLong Focus Capital Management, LLC (Filed by)Vincerx Pharma (Subject)Form SCHEDULE 13G/A02/06/20253:05 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/06/20253:06 PMVincerx Pharma (Filer)Form DEFA14A01/29/20253:05 PMVincerx Pharma (Filer)Form DEFA14A01/23/20253:10 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/23/20253:13 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/23/20253:15 PMVincerx Pharma (Filer)Form DEFA14A01/21/20253:31 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/21/20253:29 PMVincerx Pharma (Filer)Form 424B501/16/20254:11 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 12/27/20243:12 PMVincerx Pharma (Filer)Form 424B512/27/20243:13 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/25/20244:05 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/14/202410:57 AMBANK OF AMERICA CORP /DE/ (Filed by)Vincerx Pharma (Subject)Form SC 13G/A11/13/20247:32 AMProsight Management, LP (Filed by)Vincerx Pharma (Subject)Form SC 13G/AGenesis 14:13-17 [HIDDEN MEANING?] (Ad)A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.Watch the presentation on America’s hidden birthright11/05/20248:15 AMVincerx Pharma (Filer)Form PRE 14A09/30/20245:57 AMVincerx Pharma (Subject)Form SC TO-I/A09/10/20243:02 PMVincerx Pharma (Subject)Form SC TO-I/A08/16/20243:01 PMVincerx Pharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Panbela Therapeutics SEC Filings Hepion Pharmaceuticals SEC Filings ZyVersa Therapeutics SEC Filings Biophytis SEC Filings Viracta Therapeutics SEC Filings Trevena SEC Filings MyMD Pharmaceuticals SEC Filings Bon Natural Life SEC Filings Capstone Therapeutics SEC Filings NuCana SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:VINC) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access